drug
vorasidenib citrate
Marketedupdated 6mo agoby Les Laboratoires Servier SAS
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 6, 2029
~2.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Jan 16, 2039compositionUS 11345677
- Jan 16, 2039compositionUS 11345677
- Dec 4, 2035method-of-use (U-3977)US 11844758
- Dec 4, 2035method-of-use (U-3977)US 11844758
- Jul 11, 2034compositionUS 10172864
- Jul 11, 2034compositionUS 10172864
- Jul 11, 2034method-of-use (U-4286)US 12433895
- Jul 11, 2034method-of-use (U-4286)US 12433895
- Jul 11, 2034compositionUS 9579324
- Jul 11, 2034compositionUS 9579324
FDA exclusivities (4)
- Aug 6, 2031ODE-491Orphan Drug (7y)4.7y
- Aug 6, 2031ODE-491Orphan Drug (7y)4.7y
- Aug 6, 2029NCENew Chemical Entity (5y)2.7y
- Aug 6, 2029NCENew Chemical Entity (5y)2.7y
News(1)
- When drug development gets personalWhen Third Rock Ventures partner Jigar Raythatha was diagnosed with brain cancer, he found himself relying on a drug originally developed by Agios, a biotech his firm backed years before he joined.…fiercebiotech · 18d ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that